Re-Vana Therapeutics
Manufacturing · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Mcclay Research Centre 97 Lisburn Rd, Be...Phone Number
+44 2890975814Website
www.revanatx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Re-Vana Therapeutics
Re-Vana Therapeutics is focused on developing sustained release ocular biologics to alleviate the treatment burden of frequent intravitreal injections for patients with sight-threatening diseases. Their innovative technologies include biodegradable, preformed implants like EyeLief and in situ forming implants like OcuLief, designed to deliver a variety of therapeutic modalities. The company aims to improve patient care by providing controlled, sustained release of biologics, peptides, and other molecules over extended periods. Re-Vana collaborates with leading global pharmaceutical companies to advance their preformulation and preclinical studies.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Re-Vana Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Re-Vana Therapeutics has new funding data
Product Launch: Get notified when Re-Vana Therapeutics launches new products
Check out if Re-Vana Therapeutics is spiking on competitors!
Click to see if Re-Vana Therapeutics had a recent Job posting/layoffs
Re-Vana Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Re-Vana Therapeutics
Earning: See what the market has to say on Re-Vana Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Re-Vana Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Re-Vana Therapeutics
Find more new buyers
Compare Similar Companies to Re-Vana Therapeutics
Compare insights from companies similar to Re-Vana Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Re-Vana Therapeutics
<$5M
1-10
Private
$15.2M
2016
N/A
Company Profile Activity
Activity Insights
Re-Vana Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Re-Vana Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Re-Vana Therapeutics.
Re-Vana Therapeutics financials insights
Gather financial insights about Re-Vana Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$3.3M
2022
Series A
$11.9M
Re-Vana Therapeutics Tech Stack
A closer look at the technologies used by Re-Vana Therapeutics
Re-Vana Therapeutics News & Media
Boehringer partners with Re-Vana on extended-release ophthalmic therapeutics
Collaboration involves photo-crosslinked, biodegradable implants designed to enable continuous, 3-to-12-month drug delivery to treat retinal diseases.Boehringer Links with Irish Drug Delivery Start-Up Re-Vana in $1B+ Eye Deal - BioSpace
The German giant is looking to develop new drugs for undisclosed eye diseases using Re-Vana’s extended-release injectable platform to supply drugs to the eye for months at a time.Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies
Boehringer and Re-Vana enter strategic collaboration to develop extended-release eye therapies, aiming to reduce injections and improve patient outcomes.RE-VANA THERAPEUTICS RAISES $11.9 MILLION IN SERIES A FINANCING
Visionary Ventures Leads Financing Round to Support the Development of Sustained Release Ophthalmic Therapeutics BELFAST, Northern Ireland, Nov. 30, 2022 /PRNewswire/ -- Re-Vana Therapeutics Ltd, a privately-held specialty drug delivery company developing sustained-release therapeutics...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Re-Vana Therapeutics
Sign Up For FreeTo access detailed company insights
Re-Vana Therapeutics is focused on developing sustained release ocular biologics to alleviate the treatment burden of frequent intravitreal injections for patients with sight-threatening diseases. Their innovative technologies include biodegradable, preformed implants like EyeLief and in situ forming implants like OcuLief, designed to deliver a var... Read More
